{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:46:49Z","timestamp":1777463209104,"version":"3.51.4"},"reference-count":103,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre, Poland","doi-asserted-by":"publisher","award":["2017\/25\/N\/NZ7\/00544"],"award-info":[{"award-number":["2017\/25\/N\/NZ7\/00544"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Alzheimer\u2019s disease (AD) belongs to the most common forms of dementia that\ncauses a progressive loss of brain cells and leads to memory impairment and decline of other\nthinking skills. There is yet no effective treatment for AD; hence, the search for new drugs\nthat could improve memory and other cognitive functions is one of the hot research topics\nworldwide. Scientific efforts are also directed toward combating behavioral and psychological\nsymptoms of dementia, which are an integral part of the disease. Several studies have indicated\nthat glycogen synthase kinase 3 beta (GSK3&amp;#946;) plays a crucial role in the pathogenesis of\nAD. Moreover, GSK3\u03b2 inhibition provided beneficial effects on memory improvement in\nmultiple animal models of AD. The present review aimed to update the most recent reports on\nthe discovery of novel multifunctional ligands with GSK3&amp;#946; inhibitory activity as potential\ndrugs for the symptomatic and disease-modifying therapy of AD. Compounds with GSK3\u03b2\ninhibitory activity seem to be an effective pharmacological approach for treating the causes\nand symptoms of AD as they reduced neuroinflammation and pathological hallmarks in animal\nmodels of AD and provided relief from cognitive and neuropsychiatric symptoms. These\ncompounds have the potential to be used as drugs for the treatment of AD, but their precise\npharmacological, pharmacokinetic, toxicological and clinical profiles need to be defined.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327666200427100453","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T17:03:40Z","timestamp":1588007020000},"page":"1731-1745","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Multifunctional Ligands with Glycogen Synthase Kinase 3 Inhibitory Activity as a New Direction in Drug Research for Alzheimer\u2019s Disease"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-7609","authenticated-orcid":true,"given":"Agnieszka","family":"Jankowska","sequence":"first","affiliation":[{"name":"Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, 30-688 Krakow,Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0756-7232","authenticated-orcid":true,"given":"Grzegorz","family":"Sata\u0142a","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Krakow,Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-6333","authenticated-orcid":true,"given":"Andrzej J.","family":"Bojarski","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Krakow,Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2445-9759","authenticated-orcid":true,"given":"Maciej","family":"Paw\u0142owski","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, 30-688 Krakow,Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-7801","authenticated-orcid":true,"given":"Gra\u017byna","family":"Ch\u0142o\u0144-Rzepa","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, 30-688 Krakow,Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2147\/CIA.S39959","volume":"8","author":"Ferris S.H.","year":"2013","unstructured":"Ferris S.H.; Farlow M.; Language impairment in Alzheimer\u2019s disease and benefits of acetylcholinesterase inhibitors. Clin Interv Aging 2013,8,1007-1014","journal-title":"Clin Interv Aging"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13195-016-0188-8","volume":"8","author":"Prince M.","year":"2016","unstructured":"Prince M.; Ali G-C.; Guerchet M.; Prina A.M.; Albanese E.; Wu Y-T.; Recent global trends in the prevalence and incidence of dementia and survival with dementia. Alzheimers Res Ther 2016,8(1),23","journal-title":"Alzheimers Res Ther"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000481568","volume":"7","author":"Mukherjee A.","year":"2017","unstructured":"Mukherjee A.; Biswas A.; Roy A.; Biswas S.; Gangopadhyay G.; Das S.K.; Behavioural and psychological symptoms of dementia: correlates and impact on caregiver distress. Dement Geriatr Cogn Disord Extra 2017,7(3),354-365","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"ref=4","unstructured":"Dementia, World Health Organization \n Accessed on: March 19, 2020"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.4103\/1673-5374.235021","volume":"13","author":"Flemmig J.","year":"2018","unstructured":"Flemmig J.; Z\u00e1mock\u00fd M.; Alia A.; Amyloid \u03b2 and free heme: bloody new insights into the pathogenesis of Alzheimer\u2019s disease. Neural Regen Res 2018,13(7),1170-1174","journal-title":"Neural Regen Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pneurobio.2018.12.006","volume":"174","author":"Sharma P.","year":"2019","unstructured":"Sharma P.; Srivastava P.; Seth A.; Tripathi P.N.; Banerjee A.G.; Shrivastava S.K.; Comprehensive review of mechanisms of pathogenesis involved in Alzheimer\u2019s disease and potential therapeutic strategies. Prog Neurobiol 2019,174,53-89","journal-title":"Prog Neurobiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2174\/0929867324666170529122802","volume":"25","author":"Jankowska A.","year":"2018","unstructured":"Jankowska A.; Weso\u0142owska A.; Paw\u0142owski M.; Ch\u0142o\u0144-Rzepa G.; Multi-target-directed ligands affecting serotonergic neurotransmission for alzheimer\u2019s disease therapy: advances in chemical and biological research. Curr Med Chem 2018,25(17),2045-2067","journal-title":"Curr Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"14727","DOI":"10.1038\/ncomms14727","volume":"8","author":"Nobili A.","year":"2017","unstructured":"Nobili A.; Latagliata E.C.; Viscomi M.T.; Cavallucci V.; Cutuli D.; Giacovazzo G.; Krashia P.; Rizzo F.R.; Marino R.; Federici M.; De Bartolo P.; Aversa D.; Dell\u2019Acqua M.C.; Cordella A.; Sancandi M.; Keller F.; Petrosini L.; Puglisi-Allegra S.; Mercuri N.B.; Coccurello R.; Berretta N.; D\u2019Amelio M.; Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer\u2019s disease. Nat Commun 2017,8(1),14727","journal-title":"Nat Commun"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fnagi.2016.00031","volume":"8","author":"Li Y.","year":"2016","unstructured":"Li Y.; Sun H.; Chen Z.; Xu H.; Bu G.; Zheng H.; Implications of GABAergic neurotransmission in Alzheimer\u2019s disease. Front Aging Neurosci 2016,8,31","journal-title":"Front Aging Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neuropharm.2015.05.007","volume":"106","author":"Zlomuzica A.","year":"2016","unstructured":"Zlomuzica A.; Dere D.; Binder S.; De Souza Silva M.A.; Huston J.P.; Dere E.; Neuronal histamine and cognitive symptoms in Alzheimer\u2019s disease. Neuropharmacology 2016,106,135-145","journal-title":"Neuropharmacology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.2174\/0929867326666190710172002","volume":"26","author":"Jankowska A.","year":"2019","unstructured":"Jankowska A.; Sata\u0142a G.; Partyka A.; Weso\u0142owska A.; Bojarski A.J.; Paw\u0142owski M.; Ch\u0142o\u0144-Rzepa G.; Discovery and development of non-dopaminergic agents for the treatment of schizophrenia: overview of the preclinical and early clinical studies. Curr Med Chem 2019,26(25),4885-4913","journal-title":"Curr Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.mcna.2018.10.009","volume":"103","author":"Atri A.","year":"2019","unstructured":"Atri A.; The Alzheimer\u2019s disease clinical spectrum: diagnosis and management. Med Clin North Am 2019,103(2),263-293","journal-title":"Med Clin North Am"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.2174\/0929867324666170705123509","volume":"24","author":"Lazarevic-Pasti T.","year":"2017","unstructured":"Lazarevic-Pasti T.; Leskovac A.; Momic T.; Petrovic S.; Vasic V.; Modulators of acetylcholinesterase activity: from Alzheimer\u2019s disease to anti-cancer drugs. Curr Med Chem 2017,24(30),3283-3309","journal-title":"Curr Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.bbadis.2013.06.012","volume":"1832","author":"Reddy P.H.","year":"2013","unstructured":"Reddy P.H.; Amyloid beta-induced glycogen synthase kinase 3\u03b2 phosphorylated VDAC1 in Alzheimer\u2019s disease: implications for synaptic dysfunction and neuronal damage. Biochim Biophys Acta 2013,1832(12),1913-1921","journal-title":"Biochim Biophys Acta"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","volume":"35","author":"Seren\u00f3 L.","year":"2009","unstructured":"Seren\u00f3 L.; Coma M.; Rodr\u00edguez M.; S\u00e1nchez-Ferrer P.; S\u00e1nchez M.B.; Gich I.; Agull\u00f3 J.M.; P\u00e9rez M.; Avila J.; Guardia-Laguarta C.; Clarim\u00f3n J.; Lle\u00f3 A.; G\u00f3mez-Isla T.; A novel GSK-3\u03b2 inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009,35(3),359-367","journal-title":"Neurobiol Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuropharm.2017.01.020","volume":"117","author":"Crofton E.J.","year":"2017","unstructured":"Crofton E.J.; Nenov M.N.; Zhang Y.; Scala F.; Page S.A.; McCue D.L.; Li D.; Hommel J.D.; Laezza F.; Green T.A.; Glycogen synthase kinase 3 beta alters anxiety-, depression- and addiction-related behaviors and neuronal activity in the nucleus accumbens shell. Neuropharmacology 2017,117,49-60","journal-title":"Neuropharmacology"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1101\/lm.038083.115","volume":"22","author":"Venna V.R.","year":"2015","unstructured":"Venna V.R.; Benashski S.E.; Chauhan A.; McCullough L.D.; Inhibition of glycogen synthase kinase-3\u03b2 enhances cognitive recovery after stroke: the role of TAK1. Learn Mem 2015,22(7),336-343","journal-title":"Learn Mem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3389\/fnagi.2017.00434","volume":"9","author":"Nguyen T.","year":"2018","unstructured":"Nguyen T.; Fan T.; George S.R.; Perreault M.L.; Disparate effects of lithium and a gsk-3 inhibitor on neuronal oscillatory activity in prefrontal cortex and hippocampus. Front Aging Neurosci 2018,9,434","journal-title":"Front Aging Neurosci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1017\/S1461145704004535","volume":"7","author":"Gould T.D.","year":"2004","unstructured":"Gould T.D.; Einat H.; Bhat R.; Manji H.K.; AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004,7(4),387-390","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1161\/ATVBAHA.118.311363","volume":"38","author":"Wang L.","year":"2018","unstructured":"Wang L.; Wang Y.; Zhang C.; Li J.; Meng Y.; Dou M.; Noguchi C.T.; Di L.; Inhibiting glycogen synthase kinase 3 reverses obesity-induced white adipose tissue inflammation by regulating apoptosis inhibitor of macrophage\/CD5L-mediated macrophage migration. Arterioscler Thromb Vasc Biol 2018,38(9),2103-2116","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/381029","volume":"2012","author":"Kramer T.","year":"2012","unstructured":"Kramer T.; Schmidt B.; Lo Monte F.; Small-molecule inhibitors of GSK-3: structural insights and their application to Alzheimer\u2019s disease models. Int J Alzheimers Dis 2012,2012","journal-title":"Int J Alzheimers Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1242\/jcs.00384","volume":"116","author":"Doble B.W.","year":"2003","unstructured":"Doble B.W.; Woodgett J.R.; GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003,116(Pt 7),1175-1186","journal-title":"J Cell Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-15-2240","volume":"23","author":"Walz A.","year":"2017","unstructured":"Walz A.; Ugolkov A.; Chandra S.; Kozikowski A.; Carneiro B.A.; O\u2019Halloran T.V.; Giles F.J.; Billadeau D.D.; Mazar A.P.; Molecular pathways: revisiting glycogen synthase kinase-3\u03b2 as a target for the treatment of cancer. Clin Cancer Res 2017,23(8),1891-1897","journal-title":"Clin Cancer Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ejmech.2017.11.103","volume":"144","author":"Saraswati A.P.","year":"2018","unstructured":"Saraswati A.P.; Ali Hussaini S.M.; Krishna N.H.; Babu B.N.; Kamal A.; Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions. Eur J Med Chem 2018,144,843-858","journal-title":"Eur J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","volume":"148","author":"Beurel E.","year":"2015","unstructured":"Beurel E.; Grieco S.F.; Jope R.S.; Glycogen synthase kinase-3 (GSK3): regulation, actions and diseases. Pharmacol Ther 2015,148,114-131","journal-title":"Pharmacol Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13287-019-1382-y","volume":"10","author":"Jiang Y.","year":"2019","unstructured":"Jiang Y.; Liu F.; Zou F.; Zhang Y.; Wang B.; Zhang Y.; Lian A.; Han X.; Liu Z.; Liu X.; Jin M.; Wang D.; Li G.; Liu J.; PBX homeobox 1 enhances hair follicle mesenchymal stem cell proliferation and reprogramming through activation of the AKT\/glycogen synthase kinase signaling pathway and suppression of apoptosis. Stem Cell Res Ther 2019,10(1),268","journal-title":"Stem Cell Res Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1016\/j.celrep.2018.04.045","volume":"23","author":"Martin S.A.","year":"2018","unstructured":"Martin S.A.; Souder D.C.; Miller K.N.; Clark J.P.; Sagar A.K.; Eliceiri K.W.; Puglielli L.; Beasley T.M.; Anderson R.M.; GSK3\u03b2 regulates brain energy metabolism. Cell Rep 2018,23(7),1922-1931.e4","journal-title":"Cell Rep"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/720689","volume":"2013","author":"Chang Y-T.","year":"2013","unstructured":"Chang Y-T.; Chen C-L.; Lin C-F.; Lu S-L.; Cheng M-H.; Kuo C-F.; Lin Y-S.; Regulatory role of GSK-3 \u03b2 on NF- \u03baB, nitric oxide and TNF- \u03b1 in group A streptococcal infection. Mediators Inflamm 2013,2013","journal-title":"Mediators Inflamm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.dci.2017.03.022","volume":"73","author":"Li X.","year":"2017","unstructured":"Li X.; Jia Z.; Wang W.; Wang L.; Liu Z.; Yang B.; Jia Y.; Song X.; Yi Q.; Qiu L.; Song L.; Glycogen synthase kinase-3 (GSK3) regulates TNF production and haemocyte phagocytosis in the immune response of Chinese mitten crab Eriocheir sinensis. Dev Comp Immunol 2017,73,144-155","journal-title":"Dev Comp Immunol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.toxrep.2018.06.002","volume":"5","author":"Kadry M.O.","year":"2018","unstructured":"Kadry M.O.; Abdel-Megeed R.M.; El-Meliegy E.; Abdel-Hamid A.Z.; Crosstalk between GSK-3, c-Fos, NF\u03baB and TNF-\u03b1 signaling pathways play an ambitious role in chitosan nanoparticles cancer therapy. Toxicol Rep 2018,5,723-727","journal-title":"Toxicol Rep"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/FNN.1000S2006","volume":"5","author":"Singh A.V.","year":"2019","unstructured":"Singh A.V.; Gemmati D.; Vats T.; Singh A.; Zamboni P.; High throughput array technologies: expanding applications from clinics to applied research. Front Nanosci Nanotechnol 2019,5(1),1-2","journal-title":"Front Nanosci Nanotechnol"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119394","volume":"219","author":"Singh A.V.","year":"2019","unstructured":"Singh A.V.; Dad Ansari M.H.; Dayan C.B.; Giltinan J.; Wang S.; Yu Y.; Kishore V.; Laux P.; Luch A.; Sitti M.; Multifunctional magnetic hairbot for untethered osteogenesis, ultrasound contrast imaging and drug delivery. Biomaterials 2019,219","journal-title":"Biomaterials"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","volume":"104","author":"Hooper C.","year":"2008","unstructured":"Hooper C.; Killick R.; Lovestone S.; The GSK3 hypothesis of Alzheimer\u2019s disease. J Neurochem 2008,104(6),1433-1439","journal-title":"J Neurochem"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/189728","volume":"2011","author":"Salcedo-Tello P.","year":"2011","unstructured":"Salcedo-Tello P.; Ortiz-Matamoros A.; Arias C.; GSK3 Function in the brain during development, neuronal plasticity and neurodegeneration. Int J Alzheimers Dis 2011,2011","journal-title":"Int J Alzheimers Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnmol.2012.00014","volume":"5","author":"Freland L.","year":"2012","unstructured":"Freland L.; Beaulieu J-M.; Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 2012,5,14","journal-title":"Front Mol Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fnmol.2011.00032","volume":"4","author":"Eldar-Finkelman H.","year":"2011","unstructured":"Eldar-Finkelman H.; Martinez A.; GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci 2011,4,32","journal-title":"Front Mol Neurosci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-5521(00)00025-9","volume":"7","author":"Coghlan M.P.","year":"2000","unstructured":"Coghlan M.P.; Culbert A.A.; Cross D.A.; Corcoran S.L.; Yates J.W.; Pearce N.J.; Rausch O.L.; Murphy G.J.; Carter P.S.; Roxbee Cox L.; Mills D.; Brown M.J.; Haigh D.; Ward R.W.; Smith D.G.; Murray K.J.; Reith A.D.; Holder J.C.; Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000,7(10),793-803","journal-title":"Chem Biol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1021\/jm701582f","volume":"51","author":"Stukenbrock H.","year":"2008","unstructured":"Stukenbrock H.; Mussmann R.; Geese M.; Ferandin Y.; Lozach O.; Lemcke T.; Kegel S.; Lomow A.; Burk U.; Dohrmann C.; Meijer L.; Austen M.; Kunick C.; 9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic \u03b2 cell protection and replication. J Med Chem 2008,51(7),2196-2207","journal-title":"J Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1074\/jbc.M002466200","volume":"276","author":"Leclerc S.","year":"2001","unstructured":"Leclerc S.; Garnier M.; Hoessel R.; Marko D.; Bibb J.A.; Snyder G.L.; Greengard P.; Biernat J.; Wu Y-Z.; Mandelkow E-M.; Eisenbrand G.; Meijer L.; Indirubins inhibit glycogen synthase kinase-3 \u03b2 and CDK5\/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer\u2019s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001,276(1),251-260","journal-title":"J Biol Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1021\/jm021095d","volume":"46","author":"Olesen P.H.","year":"2003","unstructured":"Olesen P.H.; S\u00f8rensen A.R.; Urs\u00f8 B.; Kurtzhals P.; Bowler A.N.; Ehrbar U.; Hansen B.F.; Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors. J Med Chem 2003,46(15),3333-3341","journal-title":"J Med Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.bmcl.2010.01.072","volume":"20","author":"Arnost M.","year":"2010","unstructured":"Arnost M.; Pierce A.; ter Haar E.; Lauffer D.; Madden J.; Tanner K.; Green J.; 3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta. Bioorg Med Chem Lett 2010,20(5),1661-1664","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1016\/j.bmcl.2007.07.056","volume":"17","author":"Shin D.","year":"2007","unstructured":"Shin D.; Lee S-C.; Heo Y-S.; Lee W-Y.; Cho Y-S.; Kim Y.E.; Hyun Y-L.; Cho J.M.; Lee Y.S.; Ro S.; Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta. Bioorg Med Chem Lett 2007,17(20),5686-5689","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.bmcl.2011.01.017","volume":"21","author":"Coffman K.","year":"2011","unstructured":"Coffman K.; Brodney M.; Cook J.; Lanyon L.; Pandit J.; Sakya S.; Schachter J.; Tseng-Lovering E.; Wessel M.; 6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3\u03b2 inhibitors. Bioorg Med Chem Lett 2011,21(5),1429-1433","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.7150\/thno.14334","volume":"6","author":"Pandey M.K.","year":"2016","unstructured":"Pandey M.K.; DeGrado T.R.; Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging. Theranostics 2016,6(4),571-593","journal-title":"Theranostics"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"6914","DOI":"10.1016\/j.bmc.2009.08.042","volume":"17","author":"Perez D.I.","year":"2009","unstructured":"Perez D.I.; Conde S.; P\u00e9rez C.; Gil C.; Simon D.; Wandosell F.; Moreno F.J.; Gelp\u00ed J.L.; Luque F.J.; Mart\u00ednez A.; Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorg Med Chem 2009,17(19),6914-6925","journal-title":"Bioorg Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejmech.2012.09.021","volume":"61","author":"Zhang P.","year":"2013","unstructured":"Zhang P.; Hu H-R.; Bian S-H.; Huang Z-H.; Chu Y.; Ye D-Y.; Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3\u03b2 (GSK-3\u03b2). Eur J Med Chem 2013,61,95-103","journal-title":"Eur J Med Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/pros.21300","volume":"71","author":"Zhu Q.","year":"2011","unstructured":"Zhu Q.; Yang J.; Han S.; Liu J.; Holzbeierlein J.; Thrasher J.B.; Li B.; Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate 2011,71(8),835-845","journal-title":"Prostate"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1089\/neu.2018.5999","volume":"36","author":"Farr S.A.","year":"2019","unstructured":"Farr S.A.; Niehoff M.L.; Kumar V.B.; Roby D.A.; Morley J.E.; Inhibition of glycogen synthase kinase 3\u03b2 as a treatment for the prevention of cognitive deficits after a traumatic brain injury. J Neurotrauma 2019,36(11),1869-1875","journal-title":"J Neurotrauma"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.neuropharm.2016.12.019","volume":"116","author":"P\u00e9rez-Domper P.","year":"2017","unstructured":"P\u00e9rez-Domper P.; Palomo V.; Gradari S.; Gil C.; de Ceballos M.L.; Mart\u00ednez A.; Trejo J.L.; The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology 2017,116,174-187","journal-title":"Neuropharmacology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/npp.2013.128","volume":"38","author":"Liu R-J.","year":"2013","unstructured":"Liu R-J.; Fuchikami M.; Dwyer J.M.; Lepack A.E.; Duman R.S.; Aghajanian G.K.; GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013,38(11),2268-2277","journal-title":"Neuropsychopharmacology"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/syn.20839","volume":"65","author":"Lipina T.V.","year":"2011","unstructured":"Lipina T.V.; Kaidanovich-Beilin O.; Patel S.; Wang M.; Clapcote S.J.; Liu F.; Woodgett J.R.; Roder J.C.; Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse 2011,65(3),234-248","journal-title":"Synapse"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/med.10011","volume":"22","author":"Martinez A.","year":"2002","unstructured":"Martinez A.; Castro A.; Dorronsoro I.; Alonso M.; Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer and inflammation. Med Res Rev 2002,22(4),373-384","journal-title":"Med Res Rev"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nature01640","volume":"423","author":"Phiel C.J.","year":"2003","unstructured":"Phiel C.J.; Wilson C.A.; Lee V.M.; Klein P.S.; GSK-3alpha regulates production of Alzheimer\u2019s disease amyloid-beta peptides. Nature 2003,423(6938),435-439","journal-title":"Nature"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1523\/JNEUROSCI.4321-06.2007","volume":"27","author":"Rockenstein E.","year":"2007","unstructured":"Rockenstein E.; Torrance M.; Adame A.; Mante M.; Bar-on P.; Rose J.B.; Crews L.; Masliah E.; Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer\u2019s disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007,27(8),1981-1991","journal-title":"J Neurosci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.brainres.2007.10.064","volume":"1188","author":"Koh S.H.","year":"2008","unstructured":"Koh S.H.; Noh M.Y.; Kim S.H.; Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res 2008,1188,254-262","journal-title":"Brain Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.3390\/ijms18122679","volume":"18","author":"Won E.","year":"2017","unstructured":"Won E.; Kim Y-K.; An oldie but goodie: lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms. Int J Mol Sci 2017,18(12),2679","journal-title":"Int J Mol Sci"},{"key":"ref=57","unstructured":"U.S. National Library of Medicine, Clinical trials.gov. Available at: Access date March 19, 2020."},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/molecules24071377","volume":"24","author":"Armagan G.","year":"2019","unstructured":"Armagan G.; Sevgili E.; G\u00fcrkan F.T.; K\u00f6se F.A.; Bilgi\u00e7 T.; Dagc\u0131 T.; Saso L.; Regulation of the Nrf2 pathway by glycogen synthase kinase-3\u03b2 in MPP-induced cell damage. Molecules 2019,24(7),1377","journal-title":"Molecules"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-141959","volume":"45","author":"Lovestone S.","year":"2015","unstructured":"Lovestone S.; Boada M.; Dubois B.; H\u00fcll M.; Rinne J.O.; Huppertz H.J.; Calero M.; Andr\u00e9s M.V.; G\u00f3mez-Carrillo B.; Le\u00f3n T.; del Ser T.; A phase II trial of tideglusib in Alzheimer\u2019s disease. J Alzheimers Dis ARGO investigators2015,45(1),75-88","journal-title":"J Alzheimers Dis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/ejn.13923","volume":"47","author":"Fuchs C.","year":"2018","unstructured":"Fuchs C.; Fustini N.; Trazzi S.; Gennaccaro L.; Rimondini R.; Ciani E.; Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice. Eur J Neurosci 2018,47(9),1054-1066","journal-title":"Eur J Neurosci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.neuropharm.2012.06.032","volume":"64","author":"Lipina T.V.","year":"2013","unstructured":"Lipina T.V.; Palomo V.; Gil C.; Martinez A.; Roder J.C.; Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL\/6J mice. Neuropharmacology 2013,64,205-214","journal-title":"Neuropharmacology"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1471-4159.2012.07866.x","volume":"122","author":"Sus\u00edn C.","year":"2012","unstructured":"Sus\u00edn C.; Morales-Garcia J.A.; Aguilar-Morante D.; Palomo V.; Sanz-Sancristobal M.; Alonso-Gil S.; Gil C.; Santos A.; Martinez A.; Perez-Castillo A.; The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. J Neurochem 2012,122(6),1193-1202","journal-title":"J Neurochem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4103\/0253-7613.169593","volume":"47","author":"Murthy V.S.","year":"2015","unstructured":"Murthy V.S.; Mangot A.G.; Psychiatric aspects of phosphodiesterases: An overview. Indian J Pharmacol 2015,47(6),594-599","journal-title":"Indian J Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2174\/0929867324666170116125159","volume":"24","author":"Jankowska A.","year":"2017","unstructured":"Jankowska A.; \u015awierczek A.; Ch\u0142o\u0144-Rzepa G.; Paw\u0142owski M.; Wyska E.; PDE7-selective and dual inhibitors: advances in chemical and biological research. Curr Med Chem 2017,24(7),673-700","journal-title":"Curr Med Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.2174\/0929867326666190620095623","volume":"27","author":"Jankowska A.","year":"2019","unstructured":"Jankowska A.; Weso\u0142owska A.; Paw\u0142owski M.; Ch\u0142o\u0144-Rzepa G.; Multifunctional ligands targeting phosphodiesterase as the future strategy for the symptomatic and disease-modifying treatment of alzheimer\u2019s disease. Curr Med Chem 2019,27(32),5351-5373","journal-title":"Curr Med Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ejmech.2018.09.021","volume":"158","author":"Ch\u0142o\u0144-Rzepa G.","year":"2018","unstructured":"Ch\u0142o\u0144-Rzepa G.; \u015alusarczyk M.; Jankowska A.; Gawalska A.; Bucki A.; Ko\u0142aczkowski M.; \u015awierczek A.; Pociecha K.; Wyska E.; Zygmunt M.; Kazek G.; Sa\u0142at K.; Paw\u0142owski M.; Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4\/7 inhibitors: A new approach for the treatment of pain. Eur J Med Chem 2018,158,517-533","journal-title":"Eur J Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ejmech.2018.01.068","volume":"146","author":"Ch\u0142o\u0144-Rzepa G.","year":"2018","unstructured":"Ch\u0142o\u0144-Rzepa G.; Jankowska A.; \u015alusarczyk M.; \u015awierczek A.; Pociecha K.; Wyska E.; Bucki A.; Gawalska A.; Ko\u0142aczkowski M.; Paw\u0142owski M.; Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4\/7 inhibitors with potential anti-inflammatory activity: design, synthesis and biological evaluation. Eur J Med Chem 2018,146,381-394","journal-title":"Eur J Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172779","volume":"865","author":"W\u00f3jcik-Pszczo\u0142a K.","year":"2019","unstructured":"W\u00f3jcik-Pszczo\u0142a K.; Ch\u0142o\u0144-Rzepa G.; Jankowska A.; Ellen E.; \u015awierczek A.; Pociecha K.; Koczurkiewicz P.; Piska K.; Gaw\u0119dzka A.; Wyska E.; Knapik-Czajka M.; P\u0119kala E.; Gosens R.; Novel phosphodiesterases inhibitors from the group of purine-2,6-dione derivatives as potent modulators of airway smooth muscle cell remodelling. Eur J Pharmacol 2019,865","journal-title":"Eur J Pharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"45701","DOI":"10.1038\/srep45701","volume":"7","author":"Gameiro I.","year":"2017","unstructured":"Gameiro I.; Michalska P.; Tenti G.; Cores \u00c1.; Buendia I.; Rojo A.I.; Georgakopoulos N.D.; Hern\u00e1ndez-Guijo J.M.; Teresa Ramos M.; Wells G.; L\u00f3pez M.G.; Cuadrado A.; Men\u00e9ndez J.C.; Le\u00f3n R.; Discovery of the first dual GSK3\u03b2 inhibitor\/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer\u2019s disease. Sci Rep 2017,7,45701","journal-title":"Sci Rep"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejmech.2018.12.063","volume":"168","author":"Oukoloff K.","year":"2019","unstructured":"Oukoloff K.; Coquelle N.; Bartolini M.; Naldi M.; Le Guevel R.; Bach S.; Josselin B.; Ruchaud S.; Catto M.; Pisani L.; Denora N.; Iacobazzi R.M.; Silman I.; Sussman J.L.; Buron F.; Colletier J-P.; Jean L.; Routier S.; Renard P-Y.; Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3. Eur J Med Chem 2019,168,58-77","journal-title":"Eur J Med Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1021\/acsmedchemlett.7b00463","volume":"9","author":"Jiang X-Y.","year":"2018","unstructured":"Jiang X-Y.; Chen T-K.; Zhou J-T.; He S-Y.; Yang H-Y.; Chen Y.; Qu W.; Feng F.; Sun H-P.; Dual GSK-3\u03b2\/AChE inhibitors as a new strategy for multitargeting anti-alzheimer\u2019s disease drug discovery. ACS Med Chem Lett 2018,9(3),171-176","journal-title":"ACS Med Chem Lett"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1021\/acschemneuro.5b00121","volume":"6","author":"Prati F.","year":"2015","unstructured":"Prati F.; De Simone A.; Armirotti A.; Summa M.; Pizzirani D.; Scarpelli R.; Bertozzi S.M.; Perez D.I.; Andrisano V.; Perez-Castillo A.; Monti B.; Massenzio F.; Polito L.; Racchi M.; Sabatino P.; Bottegoni G.; Martinez A.; Cavalli A.; Bolognesi M.L.; 3,4-dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1\/GSK-3\u03b2 fragment hits against alzheimer\u2019s disease. ACS Chem Neurosci 2015,6(10),1665-1682","journal-title":"ACS Chem Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.nbd.2010.03.022","volume":"39","author":"Ding Y.","year":"2010","unstructured":"Ding Y.; Qiao A.; Fan G-H.; Indirubin-3\u2032-monoxime rescues spatial memory deficits and attenuates \u03b2-amyloid-associated neuropathology in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis 2010,39(2),156-168","journal-title":"Neurobiol Dis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ejmech.2017.06.017","volume":"138","author":"Brogi S.","year":"2017","unstructured":"Brogi S.; Ramunno A.; Savi L.; Chemi G.; Alfano G.; Pecorelli A.; Pambianchi E.; Galatello P.; Compagnoni G.; Focher F.; Biamonti G.; Valacchi G.; Butini S.; Gemma S.; Campiani G.; Brindisi M.; First dual AK\/GSK-3\u03b2 inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents. Eur J Med Chem 2017,138,438-457","journal-title":"Eur J Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.1021\/acs.jmedchem.8b00610","volume":"61","author":"Gandini A.","year":"2018","unstructured":"Gandini A.; Bartolini M.; Tedesco D.; Martinez-Gonzalez L.; Roca C.; Campillo N.E.; Zaldivar-Diez J.; Perez C.; Zuccheri G.; Miti A.; Feoli A.; Castellano S.; Petralla S.; Monti B.; Rossi M.; Moda F.; Legname G.; Martinez A.; Bolognesi M.L.; Tau-centric multitarget approach for alzheimer\u2019s disease: development of first-in-class dual glycogen synthase kinase 3\u03b2 and tau-aggregation inhibitors. J Med Chem 2018,61(17),7640-7656","journal-title":"J Med Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1021\/acsmedchemlett.8b00507","volume":"10","author":"De Simone A.","year":"2019","unstructured":"De Simone A.; La Pietra V.; Betari N.; Petragnani N.; Conte M.; Daniele S.; Pietrobono D.; Martini C.; Petralla S.; Casadei R.; Davani L.; Frabetti F.; Russomanno P.; Novellino E.; Montanari S.; Tumiatti V.; Ballerini P.; Sarno F.; Nebbioso A.; Altucci L.; Monti B.; Andrisano V.; Milelli A.; Discovery of the first-in-class GSK-3\u03b2\/HDAC dual inhibitor as disease-modifying agent to combat alzheimer\u2019s disease. ACS Med Chem Lett 2019,10(4),469-474","journal-title":"ACS Med Chem Lett"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ejmech.2018.12.003","volume":"163","author":"Bisi A.","year":"2019","unstructured":"Bisi A.; Arribas R.L.; Micucci M.; Budriesi R.; Feoli A.; Castellano S.; Belluti F.; Gobbi S.; de Los Rios C.; Rampa A.; Polycyclic maleimide-based derivatives as first dual modulators of neuronal calcium channels and GSK-3\u03b2 for Alzheimer\u2019s disease treatment. Eur J Med Chem 2019,163,394-402","journal-title":"Eur J Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-018-08523-5","volume":"21","author":"Bahn G.","year":"2019","unstructured":"Bahn G.; Jo D-G.; Therapeutic approaches to alzheimer\u2019s disease through modulation of NRF2. Neuromolecular Med 2019,21(1),1-11","journal-title":"Neuromolecular Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/jnr.24357","volume":"97","author":"Tian Y.","year":"2019","unstructured":"Tian Y.; Wang W.; Xu L.; Li H.; Wei Y.; Wu Q.; Jia J.; Activation of Nrf2\/ARE pathway alleviates the cognitive deficits in PS1V97L-Tg mouse model of Alzheimer\u2019s disease through modulation of oxidative stress. J Neurosci Res 2019,97(4),492-505","journal-title":"J Neurosci Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/13506129.2012.751367","volume":"20","author":"Kim H.V.","year":"2013","unstructured":"Kim H.V.; Kim H.Y.; Ehrlich H.Y.; Choi S.Y.; Kim D.J.; Kim Y.; Amelioration of Alzheimer\u2019s disease by neuroprotective effect of sulforaphane in animal model. Amyloid 2013,20(1),7-12","journal-title":"Amyloid"},{"key":"ref=81","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101089","volume":"21","author":"Fischer W.","year":"2019","unstructured":"Fischer W.; Currais A.; Liang Z.; Pinto A.; Maher P.; Old age-associated phenotypic screening for Alzheimer\u2019s disease drug candidates identifies sterubin as a potent neuroprotective compound from Yerba santa. Redox Biol 2019,21","journal-title":"Redox Biol"},{"key":"ref=82","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708604","volume":"10","author":"Ranea-Robles P.","year":"2018","unstructured":"Ranea-Robles P.; Launay N.; Ruiz M.; Calingasan N.Y.; Dumont M.; Naud\u00ed A.; Portero-Ot\u00edn M.; Pamplona R.; Ferrer I.; Beal M.F.; Fourcade S.; Pujol A.; Aberrant regulation of the GSK-3\u03b2\/NRF2 axis unveils a novel therapy for adrenoleukodystrophy. EMBO Mol Med 2018,10(8)","journal-title":"EMBO Mol Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.redox.2017.10.010","volume":"14","author":"Cuadrado A.","year":"2018","unstructured":"Cuadrado A.; K\u00fcgler S.; Lastres-Becker I.; Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biol 2018,14,522-534","journal-title":"Redox Biol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"20196","DOI":"10.1038\/srep20196","volume":"6","author":"Chen X.","year":"2016","unstructured":"Chen X.; Liu Y.; Zhu J.; Lei S.; Dong Y.; Li L.; Jiang B.; Tan L.; Wu J.; Yu S.; Zhao Y.; GSK-3\u03b2 downregulates Nrf2 in cultured cortical neurons and in a rat model of cerebral ischemia-reperfusion. Sci Rep 2016,6,20196","journal-title":"Sci Rep"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/14737175.2018.1531706","volume":"18","author":"Panza F.","year":"2018","unstructured":"Panza F.; Lozupone M.; Solfrizzi V.; Sardone R.; Piccininni C.; Dibello V.; Stallone R.; Giannelli G.; Bellomo A.; Greco A.; Daniele A.; Seripa D.; Logroscino G.; Imbimbo B.P.; BACE inhibitors in clinical development for the treatment of Alzheimer\u2019s disease. Expert Rev Neurother 2018,18(11),847-857","journal-title":"Expert Rev Neurother"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/anie.201410456","volume":"54","author":"Prati F.","year":"2015","unstructured":"Prati F.; De Simone A.; Bisignano P.; Armirotti A.; Summa M.; Pizzirani D.; Scarpelli R.; Perez D.I.; Andrisano V.; Perez-Castillo A.; Monti B.; Massenzio F.; Polito L.; Racchi M.; Favia A.D.; Bottegoni G.; Martinez A.; Bolognesi M.L.; Cavalli A.; Multitarget drug discovery for Alzheimer\u2019s disease: triazinones as BACE-1 and GSK-3\u03b2 inhibitors. Angew Chem Int Ed Engl 2015,54(5),1578-1582","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s11224-016-0803-0","volume":"27","author":"Czele\u0144 P.","year":"2016","unstructured":"Czele\u0144 P.; Molecular dynamics study on inhibition mechanism of CDK-2 and GSK-3\u03b2 by CHEMBL272026 molecule. Struct Chem 2016,27(6),1807-1818","journal-title":"Struct Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"9589","DOI":"10.1021\/jm3008536","volume":"55","author":"Boulahjar R.","year":"2012","unstructured":"Boulahjar R.; Ouach A.; Matteo C.; Bourg S.; Ravache M.; le Gu\u00e9vel R.; Marionneau S.; Oullier T.; Lozach O.; Meijer L.; Guguen-Guillouzo C.; Lazar S.; Akssira M.; Troin Y.; Guillaumet G.; Routier S.; Novel tetrahydropyrido[1,2-a]isoindolone derivatives (valmerins): potent cyclin-dependent kinase\/glycogen synthase kinase 3 inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts. J Med Chem 2012,55(22),9589-9606","journal-title":"J Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejmech.2014.08.049","volume":"86","author":"Zhao P.","year":"2014","unstructured":"Zhao P.; Li Y.; Gao G.; Wang S.; Yan Y.; Zhan X.; Liu Z.; Mao Z.; Chen S.; Wang L.; Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)\/glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) phosphorylation inhibitors. Eur J Med Chem 2014,86,165-174","journal-title":"Eur J Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ejmech.2016.02.072","volume":"115","author":"Ouach A.","year":"2016","unstructured":"Ouach A.; Boulahjar R.; Vala C.; Bourg S.; Bonnet P.; Guguen-Guillouzo C.; Ravache M.; Le Guevel R.; Lozach O.; Lazar S.; Troin Y.; Meijer L.; Ruchaud S.; Akssira M.; Guillaumet G.; Routier S.; Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5\/GSK3 inhibitors. Eur J Med Chem 2016,115,311-325","journal-title":"Eur J Med Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.stemcr.2019.01.015","volume":"12","author":"Reinhardt L.","year":"2019","unstructured":"Reinhardt L.; Kordes S.; Reinhardt P.; Glatza M.; Baumann M.; Drexler H.C.A.; Menninger S.; Zischinsky G.; Eickhoff J.; Fr\u00f6b C.; Bhattarai P.; Arulmozhivarman G.; Marrone L.; Janosch A.; Adachi K.; Stehling M.; Anderson E.N.; Abo-Rady M.; Bickle M.; Pandey U.B.; Reimer M.M.; Kizil C.; Sch\u00f6ler H.R.; Nussbaumer P.; Klebl B.; Sterneckert J.L.; Dual inhibition of GSK3\u03b2 and CDK5 protects the cytoskeleton of neurons from neuroinflammatory-mediated degeneration in vitro and in vivo. Stem Cell Reports 2019,12(3),502-517","journal-title":"Stem Cell Reports"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neuroscience.2006.06.016","volume":"142","author":"Studer F.E.","year":"2006","unstructured":"Studer F.E.; Fedele D.E.; Marowsky A.; Schwerdel C.; Wernli K.; Vogt K.; Fritschy J.M.; Boison D.; Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. Neuroscience 2006,142(1),125-137","journal-title":"Neuroscience"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12938-018-0477-5","volume":"17","author":"Ning C.","year":"2018","unstructured":"Ning C.; Wang H.D.; Gao R.; Chang Y-C.; Hu F.; Meng X.; Huang S-Y.; Marine-derived protein kinase inhibitors for neuroinflammatory diseases. Biomed Eng Online 2018,17(1),46","journal-title":"Biomed Eng Online"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-017-0089-1","volume":"6","author":"Yang S.S.","year":"2017","unstructured":"Yang S.S.; Zhang R.; Wang G.; Zhang Y.F.; The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer\u2019s disease. Transl Neurodegener 2017,6(1),19","journal-title":"Transl Neurodegener"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ejmech.2018.03.005","volume":"150","author":"Rabal O.","year":"2018","unstructured":"Rabal O.; S\u00e1nchez-Arias J.A.; Cuadrado-Tejedor M.; de Miguel I.; P\u00e9rez-Gonz\u00e1lez M.; Garc\u00eda-Barroso C.; Ugarte A.; Estella-Hermoso de Mendoza A.; S\u00e1ez E.; Espelosin M.; Ursua S.; Haizhong T.; Wei W.; Musheng X.; Garcia-Osta A.; Oyarzabal J.; Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 2018,150,506-524","journal-title":"Eur J Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1021\/acschemneuro.9b00303","volume":"10","author":"Rabal O.","year":"2019","unstructured":"Rabal O.; S\u00e1nchez-Arias J.A.; Cuadrado-Tejedor M.; de Miguel I.; P\u00e9rez-Gonz\u00e1lez M.; Garc\u00eda-Barroso C.; Ugarte A.; Estella-Hermoso de Mendoza A.; S\u00e1ez E.; Espelosin M.; Ursua S.; Tan H.; Wu W.; Xu M.; Pineda-Lucena A.; Garcia-Osta A.; Oyarzabal J.; Multitarget Approach for the treatment of alzheimer\u2019s disease: inhibition of phosphodiesterase 9 (PDE9) and histone deacetylases (hdacs) covering diverse selectivity profiles. ACS Chem Neurosci 2019,10(9),4076-4101","journal-title":"ACS Chem Neurosci"},{"key":"ref=97","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/787805","volume":"2015","author":"Lovell M.A.","year":"2015","unstructured":"Lovell M.A.; Abner E.; Kryscio R.; Xu L.; Fister S.X.; Lynn B.C.; Calcium channel blockers, progression to dementia and effects on amyloid beta peptide production. Oxid Med Cell Longev 2015,2015","journal-title":"Oxid Med Cell Longev"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.18203\/2319-2003.ijbcp20163262","volume":"5","author":"Sekhar D.","year":"2016","unstructured":"Sekhar D.; Shwetha B.; Haimavathi B.; Vikram P.; The effect of calcium channel blockers against scopolamine induced cognitive impairment and oxidative stress. Int J Basic Clin Pharmacol 2016,5(5),2199-2211","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref=99","year":"2018","unstructured":"SwissADME was used for property prediction \n Access date March 19, 20202018"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"38553","DOI":"10.1038\/srep38553","volume":"6","author":"Medunjanin S.","year":"2016","unstructured":"Medunjanin S.; Schleithoff L.; Fiegehenn C.; Weinert S.; Zuschratter W.; Braun-Dullaeus R.C.; GSK-3\u03b2 controls NF-kappaB activity via IKK\u03b3\/NEMO. Sci Rep 2016,6(1),38553","journal-title":"Sci Rep"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-019-0578-9","volume":"12","author":"Sotolongo K.","year":"2020","unstructured":"Sotolongo K.; Ghiso J.; Rostagno A.; Nrf2 activation through the PI3K\/GSK-3 axis protects neuronal cells from A\u03b2-mediated oxidative and metabolic damage. Alzheimers Res Ther 2020,12(1),13","journal-title":"Alzheimers Res Ther"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bph.14912","volume":"177","author":"Gao J.","year":"2020","unstructured":"Gao J.; Long L.; Xu F.; Feng L.; Liu Y.; Shi J.; Gong Q.; Icariside II, a phosphodiesterase 5 inhibitor, attenuates cerebral ischaemia\/reperfusion injury by inhibiting glycogen synthase kinase-3\u03b2-mediated activation of autophagy. Br J Pharmacol 2020,177(6),1434-1452","journal-title":"Br J Pharmacol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12929-019-0613-y","volume":"27","author":"Chang P-K.","year":"2020","unstructured":"Chang P-K.; Chu J.; Tsai Y-T.; Lai Y-H.; Chen J-C.; Dopamine D3 receptor and GSK3\u03b2 signaling mediate deficits in novel object recognition memory within dopamine transporter knockdown mice. J Biomed Sci 2020,27(1),16","journal-title":"J Biomed Sci"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200427100453","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/181369\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200427100453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T18:35:45Z","timestamp":1660070145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181369\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200427100453","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}